BMS-823778 structure
|
Common Name | BMS-823778 | ||
---|---|---|---|---|
CAS Number | 1140898-87-8 | Molecular Weight | 364.269 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C18H18ClN3O·HCl | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of BMS-823778BMS-823778 (BMS823778) is an orally available, potent and selective inhibitor of 11βHSD-1 with IC50 of 2.3 nM, displays >10,000-fold selectivity over 11βHSD-2; exhibits robust acute pharmacodynamic effects in cynomolgus monkeys (ED50=0.6mg/Kg) and in diet-induced obese (DIO) mice (ED50=34 mg/Kg), also showed excellent inhibition in an ex vivo adipose DIO mouse model (ED50=5.2 mg/Kg). Diabetes Phase 2 Clinical |
Name | BMS823778 |
---|---|
Synonym | More Synonyms |
Description | BMS-823778 (BMS823778) is an orally available, potent and selective inhibitor of 11βHSD-1 with IC50 of 2.3 nM, displays >10,000-fold selectivity over 11βHSD-2; exhibits robust acute pharmacodynamic effects in cynomolgus monkeys (ED50=0.6mg/Kg) and in diet-induced obese (DIO) mice (ED50=34 mg/Kg), also showed excellent inhibition in an ex vivo adipose DIO mouse model (ED50=5.2 mg/Kg). Diabetes Phase 2 Clinical |
---|---|
References | References 1. Cheng Y, et al. Br J Clin Pharmacol. 2018 Jan;84(1):130-141. 2. Jun Li, et al. Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1). ACS Med. Chem. Lett. 2018 Nov. DOI: 10.1021/acsmedchemlett.8b00307. View Related Products by Target 11β-HSD Diabetes |
Molecular Formula | C18H18ClN3O·HCl |
---|---|
Molecular Weight | 364.269 |
Exact Mass | 363.090515 |
C82R061MZ5 |
BMS 823778 |
2-{3-[1-(4-Chlorophenyl)cyclopropyl][1,2,4]triazolo[4,3-a]pyridin-8-yl}-2-propanol hydrochloride (1:1) |
3-[1-(4-Chlorophenyl)cyclopropyl]-α,α-dimethyl-1,2,4-triazolo[4,3-a]pyridine-8-methanol hydrochloride |
1,2,4-Triazolo[4,3-a]pyridine-8-methanol, 3-[1-(4-chlorophenyl)cyclopropyl]-α,α-dimethyl-, hydrochloride (1:1) |
MFCD30718574 |
BMS823778 |
Bms-823778 |
BMS-823778-03 |